PL431237A1 - New peptide for use as chondrogenesis stimulator and medicine for treatment of cartilage damage - Google Patents
New peptide for use as chondrogenesis stimulator and medicine for treatment of cartilage damageInfo
- Publication number
- PL431237A1 PL431237A1 PL431237A PL43123719A PL431237A1 PL 431237 A1 PL431237 A1 PL 431237A1 PL 431237 A PL431237 A PL 431237A PL 43123719 A PL43123719 A PL 43123719A PL 431237 A1 PL431237 A1 PL 431237A1
- Authority
- PL
- Poland
- Prior art keywords
- stimulator
- treatment
- peptide
- chondrogenesis
- medicine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000022159 cartilage development Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 206010007710 Cartilage injury Diseases 0.000 title 1
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 210000001612 chondrocyte Anatomy 0.000 abstract 2
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Przedmiotem wynalazku jest peptyd AGF9 o sekwencji aminokwasowej Thr-Ser-Arg-Gly-Asp-His-Glu-Leu-Leu-NH2 stanowiący środek o działaniu stymulującym chondrogenezę. Peptyd może być stosowany jako stymulator różnicowania komórek macierzystych tkanki tłuszczowej ASCs w chondrocyty. Wynalazek obejmuje medyczne zastosowanie peptydu AGF9 jako leku w terapii uszkodzeń chrząstki jako stymulator tworzenia nowych chondrocytów uzupełniania zdegenerowanej chrząstki, w uszkodzonych stawach, zwłaszcza w terapii chorób zwyrodnieniowych stawów.The subject of the invention is an AGF9 peptide with the amino acid sequence Thr-Ser-Arg-Gly-Asp-His-Glu-Leu-Leu-NH2, which is an agent that stimulates chondrogenesis. The peptide can be used as a stimulator of the differentiation of adipose tissue stem cells ASCs into chondrocytes. The invention encompasses the medical use of the AGF9 peptide as a drug in the treatment of cartilage defects as a stimulator of the formation of new chondrocytes to replenish degenerated cartilage in damaged joints, especially in the treatment of degenerative joint diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL431237A PL236332B1 (en) | 2019-09-21 | 2019-09-21 | New peptide for use as chondrogenesis stimulator and medicine for treatment of cartilage damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL431237A PL236332B1 (en) | 2019-09-21 | 2019-09-21 | New peptide for use as chondrogenesis stimulator and medicine for treatment of cartilage damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL431237A1 true PL431237A1 (en) | 2020-07-13 |
| PL236332B1 PL236332B1 (en) | 2020-12-28 |
Family
ID=71512457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL431237A PL236332B1 (en) | 2019-09-21 | 2019-09-21 | New peptide for use as chondrogenesis stimulator and medicine for treatment of cartilage damage |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL236332B1 (en) |
-
2019
- 2019-09-21 PL PL431237A patent/PL236332B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL236332B1 (en) | 2020-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000120A (en) | USE OF AN AADC VIRAL VECTOR FOR THE TREATMENT OF AADC DEFICIENCY. | |
| JP2016510763A5 (en) | ||
| MX2023008626A (en) | Therapeutic recombinant klotho proteins and compositions and methods involving the same. | |
| PE20142332A1 (en) | METHOD AND FORMULATION TO REDUCE THE AGGREGATION OF A MACROMOLECLE UNDER PHYSIOLOGICAL CONDITIONS | |
| MX2019005687A (en) | Novel recombinant klotho proteins and compositions and methods involving the same. | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| BR112014007675A2 (en) | degenerative joint disease treatment | |
| AR081680A1 (en) | METHODS AND COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF N-ACETYL GLUCOSAMINIDASE | |
| CN102026546A (en) | Compositions and methods for cartilage repair | |
| GB2562406A (en) | A method of non destructive monitoring of biological processes in microfluidic tissue culture systems | |
| MX2020007495A (en) | Group b adenovirus-containing formulation. | |
| WO2011112856A3 (en) | Novel protein peptide hydrogels | |
| MX2021012041A (en) | Methods of promoting thymic epithelial cell and thymic epithelial cell progenitor differentiation of pluripotent stem cells. | |
| AR095076A1 (en) | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE | |
| JOP20190019A1 (en) | Pharmaceutical Formula for Treatment of Growth Hormone Deficiency Contains Human Growth Hormone (hGH) Fusion Protein | |
| PL431237A1 (en) | New peptide for use as chondrogenesis stimulator and medicine for treatment of cartilage damage | |
| ZA202101688B (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain | |
| BR112018008769A2 (en) | pharmaceutical formulations, reconstituted and lyophilized aqueous liquid formulations, syringe, method of manufacturing a pharmaceutical formulation, method for treating a disease and use of a reconstructed formulation | |
| MX2018011121A (en) | Preventing biological tissue adhesion. | |
| JP2019503341A5 (en) | ||
| CA3247428A1 (en) | Pharmaceutical compositions of therapeutic proteins and methods of use | |
| ES2616004T3 (en) | Prophylactic agent and / or therapeutic agent and / or exacerbating suppressing agent for human knee osteortritis | |
| TW201614066A (en) | Composition for treatment of joint disease and method thereof | |
| WO2017062666A3 (en) | Enzyme replacement therapy for mucopolysaccharidosis iiid | |
| WO2018004294A3 (en) | Pharmaceutical composition comprising mutant human growth hormone protein or transferrin fusion protein thereof as effective ingredient |